# Myo-Inositol: Pharmacokinetics, Biological Functions, and Therapeutic Potential in Liver Protection: Insights from Preclinical Models

**Authors:** Tomasz Antonowski, Adam Osowski, Joanna Wojtkiewicz

PMC · DOI: 10.3390/antiox15030297 · Antioxidants · 2026-02-27

## TL;DR

Myo-inositol, a natural compound, shows liver-protecting potential by reducing oxidative stress and inflammation in preclinical models.

## Contribution

The paper reviews myo-inositol's pharmacokinetics and preclinical evidence for liver protection, suggesting its therapeutic potential.

## Key findings

- Myo-inositol has high oral bioavailability and is primarily eliminated via the kidneys.
- Preclinical studies show myo-inositol reduces oxidative stress, inflammation, and lipid accumulation in liver cells.
- Myo-inositol stabilizes liver cell membranes and may be useful in treating liver diseases and drug-induced injury.

## Abstract

Myo-inositol, the most common stereoisomer of inositol, plays an important role in many physiological processes, such as cell signaling, regulation of glucose and lipid metabolism, and protection of cells against oxidative stress. The main focus has been on pharmacokinetics, and it has been studied in both animal models (Wistar rats, mice, and Danio rerio) and humans. It is characterized by high oral bioavailability and is primarily eliminated via the kidneys. Preclinical studies have shown that myo-inositol has hepatoprotective potential, reducing oxidative stress, inflammation, and lipid accumulation in hepatocytes, as well as stabilizing liver cell membranes. Animal models make it possible to assess mechanisms of action, toxicity, and efficacy, thereby laying the groundwork for clinical research. In clinical practice, myo-inositol is currently used mainly in the treatment of polycystic ovary syndrome, gestational diabetes, fertility disorders, and certain affective disorders. Based on the results of preclinical studies, its potential application in liver diseases and drug-induced injury has been suggested. Despite promising findings, further translational research and randomized clinical trials are necessary to evaluate the therapeutic efficacy and safety of myo-inositol in hepatology. In summary, myo-inositol is a natural, well-tolerated compound with a multidirectional mechanism of action that may represent a promising element of supportive therapy for liver diseases.

## Linked entities

- **Chemicals:** myo-inositol (PubChem CID 892)
- **Diseases:** polycystic ovary syndrome (MONDO:0008487), gestational diabetes (MONDO:0005406), fertility disorders (MONDO:0005047)
- **Species:** Mus musculus (taxon 10090), Danio rerio (taxon 7955)

## Full-text entities

- **Diseases:** polycystic ovary syndrome (MESH:D011085), liver diseases (MESH:D008107), gestational diabetes (MESH:D016640), inflammation (MESH:D007249), affective disorders (MESH:D019964), toxicity (MESH:D064420), fertility disorders (MESH:D007246)
- **Chemicals:** glucose (MESH:D005947), Myo-Inositol (MESH:D007294), lipid (MESH:D008055)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024216/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024216/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024216/full.md

---
Source: https://tomesphere.com/paper/PMC13024216